Pacritinib

Overview

Pacritinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2035187).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Pacritinib expires 25 Mar 2030 and exclusivity 28 Feb 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene

Canonical SMILES

C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2

InChIKey

HWXVIOGONBBTBY-ONEGZZNKSA-N